184 related articles for article (PubMed ID: 23451862)
21. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
[TBL] [Abstract][Full Text] [Related]
22. Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.
Lin WW; Lu YC; Huang BC; Chuang CH; Cheng YA; Chen IJ; Liu HJ; Ho KW; Liao TY; Liu ES; Wu TY; Chang LS; Hong ST; Cheng TL
Sci Rep; 2021 Jul; 11(1):14846. PubMed ID: 34290297
[TBL] [Abstract][Full Text] [Related]
23. Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report.
Zayaeva AA; Sokolova LV; Shaduro DV; Petrov AV; Kulanthaivel S; Kaliberdenko VB
Curr Rheumatol Rev; 2022; 18(4):373-379. PubMed ID: 34784874
[TBL] [Abstract][Full Text] [Related]
24. Rilonacept and canakinumab.
Dubois EA; Rissmann R; Cohen AF
Br J Clin Pharmacol; 2011 May; 71(5):639-41. PubMed ID: 21375570
[No Abstract] [Full Text] [Related]
25. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
26. Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes.
Zhuang L; Chen J; Yu J; Marathe A; Sahajwalla C; Borigini M; Maynard J; Burckart GJ; Wang Y
Clin Pharmacol Ther; 2019 Sep; 106(3):557-567. PubMed ID: 30447083
[TBL] [Abstract][Full Text] [Related]
27. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
Church LD; McDermott MF
Curr Opin Mol Ther; 2009 Feb; 11(1):81-9. PubMed ID: 19169963
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Imagawa T; Nishikomori R; Takada H; Takeshita S; Patel N; Kim D; Lheritier K; Heike T; Hara T; Yokota S
Clin Exp Rheumatol; 2013; 31(2):302-9. PubMed ID: 23380020
[TBL] [Abstract][Full Text] [Related]
29. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
[TBL] [Abstract][Full Text] [Related]
30. [Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes].
Carné X
Med Clin (Barc); 2011 Jan; 136 Suppl 1():34-7. PubMed ID: 21596185
[TBL] [Abstract][Full Text] [Related]
31. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
Savic S; McDermott MF
Nat Rev Rheumatol; 2009 Oct; 5(10):529-30. PubMed ID: 19798026
[No Abstract] [Full Text] [Related]
32. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
33. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
Çakan M; Karadağ ŞG; Ayaz NA
Turk J Pediatr; 2020; 62(2):167-174. PubMed ID: 32419407
[TBL] [Abstract][Full Text] [Related]
34. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.
Sun H; Van LM; Floch D; Jiang X; Klein UR; Abrams K; Sunkara G
J Clin Pharmacol; 2016 Dec; 56(12):1516-1527. PubMed ID: 27119439
[TBL] [Abstract][Full Text] [Related]
36. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
37. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
[TBL] [Abstract][Full Text] [Related]
38. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
40. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
Rondeau JM; Ramage P; Zurini M; Gram H
MAbs; 2015; 7(6):1151-60. PubMed ID: 26284424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
